Innate and adaptive immunity in the pathogenesis of atherosclerosis

被引:790
作者
Hansson, GK
Libby, P
Schönbeck, U
Yan, ZQ
机构
[1] Karolinska Hosp, Ctr Mol Med, SE-17176 Stockholm, Sweden
[2] Karolinska Hosp, Dept Med, SE-17176 Stockholm, Sweden
[3] Harvard Univ, Sch Med, Brigham & Womens Hosp, Leducq Ctr Cardiovasc Res,Dept Med, Boston, MA 02115 USA
关键词
lymphocytes; macrophages; antibody; inflammation; cytokines;
D O I
10.1161/01.RES.0000029784.15893.10
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review considers critically the evidence for the involvement of mediators of innate and acquired immunity in various stages of atherosclerosis. Rapidly mobilized arms of innate immunity, including phagocytic leukocytes, complement, and proinflammatory cytokines, contribute to atherogenesis. In addition, adaptive immunity, with its T cells, antibodies, and immunoregulatory cytokines, powerfully modulates disease activity and progression. Atherogenesis involves cross talk between and shared pathways involved in adaptive and innate immunity. Immune processes can influence the balance between cell proliferation and death, between synthetic and degradative processes, and between pro- and antithrombotic processes. Various established and emerging risk factors for atherosclerosis modulate aspects of immune responses, including lipoproteins and their modified products, vasoactive peptides, and infectious agents. As we fill in the molecular details, new potential targets for therapies will doubtless emerge.
引用
收藏
页码:281 / 291
页数:11
相关论文
共 157 条
  • [81] Atherosclerosis
    Lusis, AJ
    [J]. NATURE, 2000, 407 (6801) : 233 - 241
  • [82] Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype
    Lutgens, E
    Cleutjens, KBJM
    Heeneman, S
    Koteliansky, VE
    Burkly, LC
    Daemen, MJAP
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (13) : 7464 - 7469
  • [83] Requirement for CD154 in the progression of atherosclerosis
    Lutgens, E
    Gorelik, L
    Daemen, MJAP
    de Muinck, E
    Grewal, IS
    Koteliansky, VE
    Flavell, RA
    [J]. NATURE MEDICINE, 1999, 5 (11) : 1313 - 1316
  • [84] Reduction of atherosclerosis in mice by inhibition of CD40 signalling
    Mach, F
    Schönbeck, U
    Sukhova, GK
    Atkinson, E
    Libby, P
    [J]. NATURE, 1998, 394 (6689) : 200 - 203
  • [85] Mach F, 1997, CIRCULATION, V96, P396
  • [86] Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis
    Mach, F
    Schonbeck, U
    Sukhova, GK
    Bourcier, T
    Bonnefoy, JY
    Pober, JS
    Libby, P
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (05) : 1931 - 1936
  • [87] Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells
    Mach, F
    Sauty, A
    Iarossi, AS
    Sukhova, GK
    Neote, K
    Libby, P
    Luster, AD
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (08) : 1041 - 1050
  • [88] Protective role of interleukin-10 in atherosclerosis
    Mallat, Z
    Besnard, S
    Duriez, M
    Deleuze, V
    Emmanuel, F
    Bureau, MF
    Soubrier, F
    Esposito, B
    Duez, H
    Fievet, C
    Staels, B
    Duverger, N
    Scherman, D
    Tedgui, A
    [J]. CIRCULATION RESEARCH, 1999, 85 (08) : E17 - E24
  • [89] Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability
    Mallat, Z
    Corbaz, A
    Scoazec, A
    Besnard, S
    Lesèche, G
    Chvatchko, Y
    Tedgui, A
    [J]. CIRCULATION, 2001, 104 (14) : 1598 - 1603
  • [90] Advances in immunology: Innate immunity.
    Medzhitov, R
    Janeway, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (05) : 338 - 344